Cancer Cell· Yehan Zhang, Shijie Tang, Yi Zhang, Jiahui Liu, Xiaohan Shi, Yikai Li, Yunguang Li, Huan Wang, Chaoliang Zhong, Maoyuan Sun, Wenjie Li, Yiqin Zhu, Weiwei Yang, Yun Zhao, Shiwei Guo, Zhongjun Wu, Lin Wang, Gang Jin, Dong Gao·· 17 小时前AI 评分40
胰腺癌对KRASG12D靶向治疗的敏感性取决于干扰素信号激活
KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer
AI 导读
Zhang等发现，胰腺癌对KRASG12D靶向治疗的内在耐药由干扰素信号受抑驱动，而该信号受抑与MYC持续活化相关。激活干扰素通路，尤其通过IFN-β，可使耐药肿瘤重新敏感，并与KRAS抑制剂产生协同作用，提示该通路是可干预靶点。
来源：Cancer Cell · cell.com